Fibrocor Therapeutics Enhances Clinical Strategy with Nephrology Experts for Alport Syndrome Fibrocor Therapeutics has appointed four leading nephrology experts to its Clinical Advisory Board, focusing on advancing treatments for Alport Syndrome.

Fibrocor Therapeutics Enhances Clinical Strategy with Nephrology Experts for Alport Syndrome #Canada #Toronto #Alport_Syndrome #Fibrocor #Nephrology_Experts

Calliditas Therapeutics Shares Positive Safety Data for Setanaxib at ASN Kidney Week Calliditas Therapeutics presented key safety data for Setanaxib in Alport syndrome patients at ASN Kidney Week, demonstrating promising results.

Calliditas Therapeutics Shares Positive Safety Data for Setanaxib at ASN Kidney Week #Sweden #Stockholm #Alport_Syndrome #Calliditas_Therapeutics #Setanaxib

Calliditas Therapeutics Showcases Groundbreaking Research at ASN Kidney Week 2025 Calliditas Therapeutics announces key data on IgAN and Alport Syndrome presented at the American Society of Nephrology Kidney Week, highlighting advancements in nephrology.

Calliditas Therapeutics Showcases Groundbreaking Research at ASN Kidney Week 2025 #USA #Houston #Calliditas #Alport_Syndrome #TARPEYO

Renalys Pharma Provides Financial Support for Alport Syndrome Registry Study in Japan Renalys Pharma is excited to announce its financial backing for a significant study on Alport Syndrome, initiated by the Japanese Society for Pediatric Nephrology.

Renalys Pharma Provides Financial Support for Alport Syndrome Registry Study in Japan #Japan #Tokyo #Renalys_Pharma #Alport_Syndrome #Pediatric_Nephrology